Varian Ranked Highest in Survey of US Radiation Oncology Professionals

Company Ranked Highest in Eight Key Performance Areas and Net Promotor Score

News provided by

Sep 16, 2019, 08:30 ET

PALO ALTO, Calif., Sept. 16, 2019 /PRNewswire/ -- Varian (NYSE: VAR) has been recognized again as a leader in the annual IMV ServiceTrak™ Radiation Oncology Systems report, ranking first in eight of the tracked categories. Additionally, Varian's Net Promotor Score improved from 71 in 2018 to 78 in 2019, and again was the highest among industry competitors. Net Promotor Scores represents the likelihood a customer would recommend a manufacturer to a colleague.

"This annual survey is very important to us because it is direct feedback from our customers," said Chris Toth, president Varian Oncology Systems. "It is a sign we are meeting and exceeding their needs and validation we are making strides in our greater goal of fighting cancer. In addition to these rankings, we are thrilled the IMV report indicates Varian's Net Promoter Score continues to improve and be higher than our industry peers."

Varian ranked first in the following eight Key Performance Categories:

Overall manufacturer
Probability of repurchase
Technology leadership
System installation
Training program
Overall system performance
System documentation
Overall service performance

The IMV ServiceTrak Radiation Oncology Systems report is a survey of U.S. hospital oncology professionals who perform therapeutic radiation oncology treatments using external beam radiation therapy systems. The survey results from interviews with 334 unique radiation therapy sites representing 511 systems. Interviews were conducted by phone from May to July, 2019.

About Varian
At Varian, we envision a world without fear of cancer. For more than 70 years, we have developed, built and delivered innovative cancer care technologies and solutions for our clinical partners around the globe to help them treat millions of patients each year. With an Intelligent Cancer Care approach, we are harnessing advanced technologies like artificial intelligence, machine learning and data analytics to enhance cancer treatment and expand access to care. Our 9,200 employees across 70 countries keep the patient and our clinical partners at the center of our thinking as we power new victories in cancer care. Because, for cancer patients everywhere, their fight is our fight. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.

About IMV
IMV Medical Information Division is a marketing research and consulting firm founded in 1977, specializing in medical imaging and other advanced healthcare technology markets. IMV is part of the Science and Medicine Group, the leading research and advisory firm serving the life science, diagnostic and analytical instrument industries. IMV's market research services, in combination with its databases of U.S. imaging sites with selected modalities, provide clients valuable assistance in strategic planning, customer satisfaction, product development and sales initiatives.

Press Contact
Mark Plungy
Director, Global Public Relations
+1 (650) 424-5630
[email protected]

Investor Relations Contact
J. Michael Bruff
Senior Vice President, Investor Relations
+1 (650) 424-5163
[email protected]

SOURCE Varian